Lyra Therapeutics Inc (LYRA)

$1.89 -0.10 (-5.03%)
Market Cap 3.66M
Revenue (ttm) 1.53M
Net Income (ttm) -93.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,107.19%
Debt to Equity Ratio 0.00
Volume 30,848
Avg Vol 86,484
Day's Range N/A - N/A
Shares Out 1.78M
Stochastic %K 16%
Beta 0.01
Analysts Hold
Price Target $11.50

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 393 4600
Address:
480 Arsenal Way, Watertown, United States
revuelto
revuelto Jan. 14 at 3:40 PM
$LYRA highly spec play I’m holding…probably giving its ip more credit than it deserves but we’ll see….I expect at least a 2x to 3x..might take a few months but likely✌️
0 · Reply
Bellbent
Bellbent Jan. 13 at 9:21 PM
$LYRA @BioGem are you buying more down here? Or selling?
1 · Reply
TIGHTSTOPLOSS
TIGHTSTOPLOSS Jan. 13 at 5:00 PM
$LYRA We are in at $1.91 here 🚀
0 · Reply
TIGHTSTOPLOSS
TIGHTSTOPLOSS Jan. 13 at 2:22 PM
$LYRA $2.25 entry only above it.
0 · Reply
Stmkr
Stmkr Jan. 13 at 9:03 AM
$LYRA Anyone? Any explanation? How is it still listing? Deadline was supposed to be 31 Dec
1 · Reply
MadMaverick
MadMaverick Jan. 13 at 1:30 AM
⚡ WATCHLIST RECAP⚡ ✅ $EVTV | +209% max profit ✅ $BDSX | +40% max profit ✅ $LYRA | +5.5% max profit ✅ $BARK | +5.6% max profit Grab the free daily watchlist by following and subscribe to get my top 5 weekly swing picks every week. Link in bio.
1 · Reply
Icemanrush16
Icemanrush16 Jan. 12 at 11:59 PM
$LYRA wow so cutting all staff - big burn rate and halting its man program …
0 · Reply
aafetygod
aafetygod Jan. 12 at 11:48 PM
$LYRA Will this stock hit $6-7 within 3 days
1 · Reply
www_larval_com
www_larval_com Jan. 12 at 8:58 PM
$NCEL 4%[14%] $GOVX 3%[-14%] $LYRA -3%[-46%] $CPSH -3%[15%] $SHMD 3%[-11%] most notable movement into the final minutes of trading.
1 · Reply
Naif_si
Naif_si Jan. 12 at 8:34 PM
$LYRA why us the drop?
0 · Reply
Latest News on LYRA
Lyra Therapeutics Provides Corporate Update

Jan 12, 2026, 7:00 AM EST - 2 days ago

Lyra Therapeutics Provides Corporate Update

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 2 months ago

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Oct 6, 2025, 7:00 AM EDT - 3 months ago

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:01 PM EDT - 5 months ago

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 27, 2025, 8:00 AM EDT - 7 months ago

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Jun 16, 2025, 4:14 PM EDT - 7 months ago

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Jun 2, 2025, 8:29 AM EDT - 8 months ago

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

May 7, 2025, 7:00 AM EDT - 9 months ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:01 PM EDT - 9 months ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 10 months ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Sep 27, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 21, 2024, 9:14 AM EDT - 1 year ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

May 6, 2024, 7:59 AM EDT - 1 year ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:04 PM EDT - 1 year ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

3 'Buy-Rated' Biotech Stocks Under $10

Apr 28, 2024, 4:39 AM EDT - 1 year ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA GERN

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 26, 2024, 4:51 PM EDT - 1 year ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 1, 2024, 4:01 PM EST - 2 years ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Nov 7, 2023, 7:00 AM EST - 2 years ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Lyra Therapeutics: Hold For Phase 3 Topline

Oct 10, 2023, 10:56 AM EDT - 2 years ago

Lyra Therapeutics: Hold For Phase 3 Topline

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Oct 9, 2023, 1:20 AM EDT - 2 years ago

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jul 13, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

Jun 1, 2023, 7:29 AM EDT - 2 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

Lyra Therapeutics Announces $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 2 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

May 9, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Apr 25, 2023, 7:59 AM EDT - 2 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Apr 5, 2023, 9:04 AM EDT - 3 years ago

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 29, 2023, 4:06 PM EDT - 3 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 27, 2023, 7:59 AM EST - 3 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Feb 6, 2023, 7:56 AM EST - 3 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 4:01 PM EST - 3 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 10, 2022, 8:00 AM EDT - 3 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 29, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

revuelto
revuelto Jan. 14 at 3:40 PM
$LYRA highly spec play I’m holding…probably giving its ip more credit than it deserves but we’ll see….I expect at least a 2x to 3x..might take a few months but likely✌️
0 · Reply
Bellbent
Bellbent Jan. 13 at 9:21 PM
$LYRA @BioGem are you buying more down here? Or selling?
1 · Reply
TIGHTSTOPLOSS
TIGHTSTOPLOSS Jan. 13 at 5:00 PM
$LYRA We are in at $1.91 here 🚀
0 · Reply
TIGHTSTOPLOSS
TIGHTSTOPLOSS Jan. 13 at 2:22 PM
$LYRA $2.25 entry only above it.
0 · Reply
Stmkr
Stmkr Jan. 13 at 9:03 AM
$LYRA Anyone? Any explanation? How is it still listing? Deadline was supposed to be 31 Dec
1 · Reply
MadMaverick
MadMaverick Jan. 13 at 1:30 AM
⚡ WATCHLIST RECAP⚡ ✅ $EVTV | +209% max profit ✅ $BDSX | +40% max profit ✅ $LYRA | +5.5% max profit ✅ $BARK | +5.6% max profit Grab the free daily watchlist by following and subscribe to get my top 5 weekly swing picks every week. Link in bio.
1 · Reply
Icemanrush16
Icemanrush16 Jan. 12 at 11:59 PM
$LYRA wow so cutting all staff - big burn rate and halting its man program …
0 · Reply
aafetygod
aafetygod Jan. 12 at 11:48 PM
$LYRA Will this stock hit $6-7 within 3 days
1 · Reply
www_larval_com
www_larval_com Jan. 12 at 8:58 PM
$NCEL 4%[14%] $GOVX 3%[-14%] $LYRA -3%[-46%] $CPSH -3%[15%] $SHMD 3%[-11%] most notable movement into the final minutes of trading.
1 · Reply
Naif_si
Naif_si Jan. 12 at 8:34 PM
$LYRA why us the drop?
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 8:20 PM
$EVTV $OMH $LVLU $LYRA
0 · Reply
UgoGreg
UgoGreg Jan. 12 at 8:17 PM
$LYRA https://youtu.be/ygBN8MilTyc
0 · Reply
UgoGreg
UgoGreg Jan. 12 at 8:11 PM
$LYRA https://youtu.be/HVy7bRK7DHA
0 · Reply
shopno
shopno Jan. 12 at 7:36 PM
$LYRA why winding down just after 7 months of publishing positive trial data? Why no big investors put capital for potential 10x return, or no cheap BO by big pharma if the data was really good? Currently have no position, as sold all in the June run up.
1 · Reply
MasterSkull
MasterSkull Jan. 12 at 7:25 PM
$LYRA - Lyra Therapeutics Provides Corporate Update!
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 6:42 PM
🚨 DarkpoolAI Live Stock Scanner! 🚨 👉 [https://x.com/DarkpoolAI/live] [Link in Bio] $EVTV We $OMH Stay $LVLU Lit $LYRA Always
0 · Reply
stockanalysis_
stockanalysis_ Jan. 12 at 6:03 PM
Losers Today: $SDM $ATRA $LYRA $NBY $LXEO Save this screener to your bookmarks: https://stockanalysis.com/markets/losers/?ref=saveontrading
0 · Reply
revuelto
revuelto Jan. 12 at 5:45 PM
$LYRA ip appeal is there and vultures will have their eye on this… if you can stomach the uncertainty, returns could be good… don’t follow me, just speaking my mind here✌️
1 · Reply
Golibajje
Golibajje Jan. 12 at 5:00 PM
$LYRA lol! same thesis here! Bought and sold couple of times this morning for profit! no ’attachment’ to this stock.. waiting for another entry at $1.80 s
0 · Reply
revuelto
revuelto Jan. 12 at 4:46 PM
$LYRA after everything is said and done I think retail could see 2x+ returns from here….it might take time but I believe we’ll get there…I’m staying in…no rational thesis at this point, just pure hopium…don’t follow me on this one 😄
0 · Reply
Neegud
Neegud Jan. 12 at 4:02 PM
$LYRA why the drop ?
0 · Reply
BOOGEYMAN_TRADEZ
BOOGEYMAN_TRADEZ Jan. 12 at 3:45 PM
$LYRA so with 1.77 M float , COE owning 1M shares and CFO owning 500K shares as per recent form 4s, and strategic alternatives announced, is this that bad at 2$?
0 · Reply